ContraFect Corp (NASDAQ:CFRX) – Equities researchers at Zacks Investment Research issued their Q1 2017 earnings per share (EPS) estimates for ContraFect Corp in a research report issued to clients and investors on Monday. Zacks Investment Research analyst D. Bautz anticipates that the brokerage will post earnings of ($0.16) per share for the quarter. Zacks Investment Research also issued estimates for ContraFect Corp’s Q2 2017 earnings at ($0.17) EPS and Q3 2017 earnings at ($0.18) EPS.
Several other equities analysts also recently weighed in on CFRX. Piper Jaffray Companies set a $5.00 target price on shares of ContraFect Corp and gave the stock a “buy” rating in a research note on Monday, November 21st. Maxim Group reaffirmed a “hold” rating on shares of ContraFect Corp in a research note on Wednesday, March 15th.
ContraFect Corp (NASDAQ:CFRX) opened at 2.00 on Tuesday. ContraFect Corp has a 12 month low of $1.35 and a 12 month high of $4.12. The firm has a 50-day moving average of $1.99 and a 200 day moving average of $2.15. The firm’s market capitalization is $83.16 million.
Institutional investors have recently modified their holdings of the stock. Baker BROS. Advisors LP bought a new stake in shares of ContraFect Corp during the third quarter valued at $10,034,000. Adage Capital Partners GP L.L.C. increased its stake in shares of ContraFect Corp by 66.7% in the third quarter. Adage Capital Partners GP L.L.C. now owns 2,500,000 shares of the company’s stock valued at $6,200,000 after buying an additional 1,000,000 shares during the last quarter. Opus Point Partners Management LLC bought a new stake in shares of ContraFect Corp during the third quarter valued at $744,000. Finally, Spark Investment Management LLC bought a new stake in shares of ContraFect Corp during the third quarter valued at $121,000. 46.18% of the stock is owned by institutional investors.